Time to progression confirmed at 3 months | |||||||||
Drug | SUCRA | IFN β-1a 44 μg SC thrice weekly | PegIFN β-1a 125 μg every 2 weeks | IFN β-1a 22 μg SC thrice weekly | IFN β-1a 30 μg IM weekly | GA 20 mg daily | IFN β-1b 250 μg SC every other day | Placebo | GA 40 mg SC thrice weekly |
IFN β-1a 44 μg SC thrice weekly | 0.77 | 1.01 (0.59, 1.74) | 0.92 (0.65, 1.30) | 0.86 (0.62, 1.19) | 0.82 (0.56, 1.22) | 0.81 (0.53, 1.22) | 0.63 (0.46, 0.86) | Not included in this analysis | |
PegIFN β-1a 125 μg every 2 weeks | 0.75 | 0.91 (0.52, 1.59) | 0.85 (0.49, 1.46) | 0.81 (0.49, 1.34) | 0.80 (0.47, 1.34) | 0.62 (0.40, 0.97) | |||
IFN β-1a 22 μg SC thrice weekly | 0.62 | 0.94 (0.62, 1.42) | 0.90 (0.59, 1.36) | 0.88 (0.57, 1.36) | 0.68 (0.49, 0.96) | ||||
IFN β-1a 30 μg IM weekly | 0.5 | 0.96 (0.65, 1.42) | 0.94 (0.62, 1.43) | 0.73 (0.53, 1.00)* | |||||
GA 20 mg daily | 0.44 | 0.98 (0.78, 1.24) | 0.76 (0.60, 0.97) | ||||||
IFN β-1b 250 μg SC every other day | 0.39 | 0.78 (0.59, 1.02) | |||||||
Placebo | 0.02 | ||||||||
Test for inconsistency (χ2, df, p) | 0.35, 2, 0.84 | ||||||||
Time to progression confirmed at 6 months | |||||||||
Drug | SUCRA | IFN β-1b 250 μg SC every other day | PegIFN β-1a 125 μg every 2 weeks | IFN β-1a 44 μg SC thrice weekly | IFN β-1a 30 μg IM weekly | GA 20 mg daily | Placebo | PegIFN β-1a 125 μg every 2 weeks | GA 40 mg thrice weekly |
IFN β-1b 250 μg SC every other day | 0.9 | 0.74 (0.32, 1.71) | 0.71 (0.32, 1.60) | 0.50 (0.29, 0.87) | 0.42 (0.21, 0.83) | 0.34 (0.18, 0.63) | Not included in this analysis | ||
PegIFN β-1a 125 μg every 2 weeks | 0.71 | 0.97 (0.40, 2.33) | 0.68 (0.35, 1.31) | 0.56 (0.28, 1.15) | 0.46 (0.26, 0.81) | ||||
IFN β-1a 44 μg SC thrice weekly | 0.7 | 0.70 (0.39, 1.25) | 0.58 (0.27, 1.27) | 0.47 (0.24, 0.93) | |||||
IFN β-1a 30 μg IM weekly | 0.4 | 0.83 (0.49, 1.41) | 0.68 (0.49, 0.94) | ||||||
GA 20 mg daily | 0.25 | 0.82 (0.53, 1.26) | |||||||
Placebo | 0.05 | ||||||||
Test for inconsistency (χ2, df, p) | 0.77, 1, 0.38 |